Saturday , June 23 2018
Home / David L. Joffe, BSPharm, CDE, FACA (page 6)

David L. Joffe, BSPharm, CDE, FACA

David L. Joffe, BSPharm, CDE, FACA
(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

Jan. 9, 2018

Almost 100 years ago, researchers figured out that the failure of the beta cells of the pancreas led to diabetes. It was more than 25 years later when we first made the distinction between type 1 and type 2 diabetes. In the next 15 years we discovered a medicine that …

Read More »

Jan. 6, 2018

When is a disease not really a disease? The answer is simple: “when the disease is diabetes.” Over the past 40 years there has been great momentum on how to change the perception. We tried lowering the target fasting levels, A1c’s and PPG values and adding new medications and monitoring …

Read More »

Jan. 3, 2018

Now that we are in the new year our patients will have every good intention on changing everything to make this their best and healthiest year ever. They will try a new exercise program and a new diet. They will swear they will take their medications and fix their glucose, …

Read More »

Dec. 30, 2017

As 2017 draws to a close, every news outlet looks back to see what things made a real difference. We have our most popular articles for each month of the year. Steve and I can also look back over the past seventeen and a half years and see what we …

Read More »

Dec 26, 2017

Today it was 81 degrees in St. Petersburg, Florida, and after a great bike ride, we were out looking at outdoor spas. This great weather often makes me forget how cold and wet it can get “up north.” When Steve sent the Disaster Averted to me to review, the last …

Read More »

Dec. 23, 2017

Happy holidays from the entire staff here at Diabetes in Control. This week we add another SGLT-2 inhibitor to our armada of diabetes medications. This new drug, Ertugliflozin, (see news flash) is coming to the market as a stand alone and in combination with both a DPP-4 inhibitor and Metformin. …

Read More »

Dec. 19, 2017

Over the past 10 years the number of car brands has decreased. GM once had 8 nameplates and now they are down to 4. They used to have a brand for every age bracket, with Buick being the name badge for their old people’s car (I can say that because …

Read More »

Dec. 16, 2017

My good friend David Kliff always seems to hit the nail on the head when it comes to evaluating diabetes companies and the battles for insurance coverage and pricing. He often discusses the idea that insulin is a commodity, and formulary choices are not based on advertised prices, but on …

Read More »

Dec 12, 2017

Today I watched a news feature on the use of robots as supervisors of humans doing jobs. Last week another show listed jobs that robots would do, and unfortunately pharmacists was one of those jobs. When you add in driverless cars and drone delivery it is not hard to see …

Read More »

Dec. 9, 2017

For many years cardiovascular disease has been the number one cause of death among diabetes patients. So getting a CV benefit from diabetes drugs is a definite plus. Over the past few weeks Dr. Aaron Vinik has been sharing his views on the values of Cycloset for both diabetes and …

Read More »